- Home
- RBNE vs CLRB Comparison
RBNE vs CLRB Comparison
Compare RBNE & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBNE | CLRB |
|---|---|---|
| Founded | 2024 | 2002 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 12.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RBNE | CLRB |
|---|---|---|
| Price | $0.77 | $3.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 219.0K | 54.5K |
| Earning Date | 10-23-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.67 | $2.71 |
| 52 Week High | $24.65 | $20.60 |
Technical Indicators
Market Signals| Indicator | RBNE | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 37.74 | 43.46 |
| Support Level | $0.85 | $3.30 |
| Resistance Level | $0.89 | $3.15 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 27.06 | 41.03 |
Price Performance
Historical ComparisonAbout RBNE Robin Energy Ltd.
Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.